What do systematic reviews say?

Organisational interventions vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 5384 participants
  Low

Educational or behavioural interventions for patients vs usual care

• Interventions for improving modifiable risk factor control in the secondary prevention of stroke 2018 · Cochrane Headline outcomes only
  no estimate extracted
  13 studies · 33762 participants
  Low

Clobazam vs phenytoin

Clobazam showed no clear difference in adverse effects requiring withdrawal/discontinuation of study… compared with phenytoin (low certainty).

• Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
  RR 0.1 [0.01, 1.65]
  1 study · 48 participants
  Low

Clobazam vs carbamazepine

The review found no eligible studies for this question.

• Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Clobazam vs phenytoin

Clobazam may leads to higher retention at 6 months (measured by the number of treatment failures… compared with phenytoin (low certainty).

• Clobazam monotherapy for focal or generalized seizures 2018 · Cochrane Headline outcomes only
  RR 1.43 [1.08, 1.9]
  1 study · 48 participants
  Low

Low‐ vs high‐energy diode trans‐scleral cyclophotocoagulation

• Cyclodestructive procedures for non‐refractory glaucoma 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 79 participants
  Moderate

Acupuncture vs gastrokinetic agents

The review found no eligible studies for this question.

• Acupuncture for symptomatic gastroparesis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupuncture vs non‐gastrokinetic agents

The review found no eligible studies for this question.

• Acupuncture for symptomatic gastroparesis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupuncture plus gastrokinetic agents vs gastrokinetic agents

The review found no eligible studies for this question.

• Acupuncture for symptomatic gastroparesis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupuncture plus non‐gastrokinetic agents vs non‐gastrokinetic agents

The review found no eligible studies for this question.

• Acupuncture for symptomatic gastroparesis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupuncture plus routine care/diabetes control vs the same treatment alone (routine care/diabetes control)

The review found no eligible studies for this question.

• Acupuncture for symptomatic gastroparesis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Acupuncture vs sham

The review found no eligible studies for this question.

• Acupuncture for symptomatic gastroparesis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

RISPERIDONE vs OLANZAPINE

The review found no eligible studies for this question.

• Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

RISPERIDONE vs CLOZAPINE ‐ all data short term

It is very uncertain whether RISPERIDONE changes adherence to antipsychotic medication: discontinued medication compared with CLOZAPINE ‐ all data short term (very low certainty).

• Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
  RR 4.05 [0.21, 78.76]
  1 study · 36 participants
  Very low

DPP‐4 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 1257 participants
  Very low

GLP‐1 agonists vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 303 participants
  Low

Glitazone vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 63 participants
  Very low

Sitagliptin vs glipizide

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 551 participants
  Very low

SGLT2 inhibitors vs placebo

• Insulin and glucose‐lowering agents for treating people with diabetes and chronic kidney disease 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 917 participants
  Very low

Ketorolac vs placebo

It is very uncertain whether ketorolac changes participants using rescue medication in the PACU compared with placebo (very low certainty).

• Ketorolac for postoperative pain in children 2018 · Cochrane Headline outcomes only
  RR 0.85 [0.71, 1]
  4 studies · 262 participants
  Very low